NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Jul 22, 2026
NeuroSense Therapeutics announced plans to file a New Drug Submission to Health Canada for its lead candidate PrimeC, following a constructive pre-submission meeting. The filing is supported by Phase 2b PARADIGM data demonstrating a statistically significant 14.9-month median survival benefit and a Hazard Ratio of 0.35. The company achieved its prespecified primary TDP-43 biomarker endpoint with a p-value of 0.0421 and presented additional mechanistic data to regulators. NeuroSense continues to prepare the submission package and expects to file in the coming months.
Key figures
- Hazard ratio
- 0.35
- Survival p value
- 0.0037
- Phase 3 enrollment target
- 300
- Primary biomarker p value
- 0.0421
- Median survival benefit months
- 14.9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.